Literature DB >> 15629359

Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences.

Thomas J Scriba1, Jan zur Megede, Richard H Glashoff, Florette K Treurnicht, Susan W Barnett, Estrelita Janse van Rensburg.   

Abstract

The efficacy of cellular immune responses elicited by HIV vaccines is dependent on their strength, durability and antigenic breadth. The regulatory proteins are abundantly expressed early in the viral life cycle and CTL recognition may bring about early killing of infected cells. We synthesised DNA vaccine constructs that encode consensus HIV-1 subtype C Tat, Rev and Nef proteins. Proteins carrying inactivating mutations were tested for functional activity and highly expressing, inactive Tat, Rev and Nef mutants were identified and their reading frames fused into a TatRevNef cassette. Single- and polygene Tat, Rev and/or Nef constructs were immunogenic in BALB/c mice. These constructs may serve to increase the antigenic breadth for an HIV-1 vaccine that is relevant for sub-Saharan Africa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629359     DOI: 10.1016/j.vaccine.2004.08.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.

Authors:  Lauren A Hirao; Ling Wu; Amir S Khan; David A Hokey; Jian Yan; Anlan Dai; Michael R Betts; Ruxandra Draghia-Akli; David B Weiner
Journal:  Vaccine       Date:  2008-03-11       Impact factor: 3.641

2.  The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.

Authors:  Petr O Ilyinskii; Anatoli B Meriin; Vladimir L Gabai; Evgeny V Usachev; Alexei G Prilipov; Galini Thoidis; Alexander M Shneider
Journal:  Protein Sci       Date:  2008-04-14       Impact factor: 6.725

3.  Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.

Authors:  Sean P McBurney; Gary Landucci; Donald N Forthal; Ted M Ross
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-21       Impact factor: 2.205

Review 4.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

5.  HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.

Authors:  Sirika Pillay; Enid G Shephard; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  J Immune Based Ther Vaccines       Date:  2010-11-19

6.  A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.

Authors:  Jan zur Megede; Brigitte Sanders-Beer; Peter Silvera; Dawn Golightly; Abigail Bowlsbey; Diane Hebblewaite; Deborah Sites; Lourdes Nieves-Duran; Ranjana Srivastava; Gillis R Otten; Dietmar Rabussay; Lei Zhang; Jeffrey B Ulmer; Susan W Barnett; John J Donnelly
Journal:  AIDS Res Hum Retroviruses       Date:  2008-08       Impact factor: 2.205

7.  Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.

Authors:  Irina Tcherepanova; Jason Harris; Aijing Starr; Jaclyn Cleveland; Helen Ketteringham; David Calderhead; Joe Horvatinovich; Don Healey; Charles A Nicolette
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.